{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:44:08Z","timestamp":1789922648322,"version":"4.0.1"},"publisher-location":"Cham","reference-count":171,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849190","type":"print"},{"value":"9783031849206","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/7854_2024_523","type":"book-chapter","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T05:02:51Z","timestamp":1730437371000},"page":"49-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cholinergic System Structure and Function Changes in Individuals with Down Syndrome During the Development of Alzheimer\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Jason K.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Ellen","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Newhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"523_CR1","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/mp.2017.183","volume":"22","author":"M Aghourian","year":"2017","unstructured":"Aghourian M, Legault-Denis C, Soucy J-P, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, B\u00e9dard M-A (2017) Quantification of brain cholinergic denervation in Alzheimer\u2019s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry 22:1531\u20131538","journal-title":"Mol Psychiatry"},{"key":"523_CR2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41593-019-0354-y","volume":"22","author":"S \u00c4hrlund-Richter","year":"2019","unstructured":"\u00c4hrlund-Richter S, Xuan Y, van Lunteren JA, Kim H, Ortiz C, Pollak Dorocic I, Meletis K, Carl\u00e9n M (2019) A whole-brain atlas of monosynaptic input targeting four different cell types in the medial prefrontal cortex of the mouse. Nat Neurosci 22:657\u2013668","journal-title":"Nat Neurosci"},{"key":"523_CR3","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cne.24541","volume":"526","author":"RL Albin","year":"2018","unstructured":"Albin RL, Bohnen NI, Muller MLTM, Dauer WT, Sarter M, Frey KA, Koeppe RA (2018) Regional vesicular acetylcholine transporter distribution in human brain: a [18F]fluoroethoxybenzovesamicol positron emission tomography study. J Comp Neurol 526:2884\u20132897","journal-title":"J Comp Neurol"},{"key":"523_CR4","doi-asserted-by":"crossref","first-page":"e22944","DOI":"10.1096\/fj.202202111RR","volume":"37","author":"MJ Alldred","year":"2023","unstructured":"Alldred MJ, Pidikiti H, Heguy A, Roussos P, Ginsberg SD (2023) Basal forebrain cholinergic neurons are vulnerable in a mouse model of Down syndrome and their molecular fingerprint is rescued by maternal choline supplementation. FASEB J 37:e22944","journal-title":"FASEB J"},{"key":"523_CR5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41583-023-00677-x","volume":"24","author":"MR Ananth","year":"2023","unstructured":"Ananth MR, Rajebhosale P, Kim R, Talmage DA, Role LW (2023) Basal forebrain cholinergic signalling: development, connectivity and roles in cognition. Nat Rev Neurosci 24:233\u2013251","journal-title":"Nat Rev Neurosci"},{"key":"523_CR6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.nicl.2013.05.006","volume":"2","author":"JS Anderson","year":"2013","unstructured":"Anderson JS, Nielsen JA, Ferguson MA, Burback MC, Cox ET, Dai L, Gerig G, Korenberg JR (2013) Abnormal brain synchrony in Down syndrome. Neuroimage Clin 2:703\u2013715","journal-title":"Neuroimage Clin"},{"key":"523_CR7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","volume":"6","author":"SE Antonarakis","year":"2020","unstructured":"Antonarakis SE, Skotko BG, Rafii MS, Strydom A, Pape SE, Bianchi DW, Sherman SL, Reeves RH (2020) Down syndrome. Nat Rev Dis Primers 6:9","journal-title":"Nat Rev Dis Primers"},{"key":"523_CR8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/ajp.156.4.564","volume":"156","author":"EH Aylward","year":"1999","unstructured":"Aylward EH, Li Q, Honeycutt NA, Warren AC, Pulsifer MB, Barta PE, Chan MD, Smith PD, Jerram M, Pearlson GD (1999) MRI volumes of the hippocampus and amygdala in adults with Down\u2019s syndrome with and without dementia. Am J Psychiatry 156:564\u2013568","journal-title":"Am J Psychiatry"},{"key":"523_CR9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0304-3940(91)90558-B","volume":"133","author":"O Bar-Peled","year":"1991","unstructured":"Bar-Peled O, Israeli M, Ben-Hur H, Hoskins I, Groner Y, Biegon A (1991) Developmental pattern of muscarinic receptors in normal and Down\u2019s syndrome fetal brain \u2013 an autoradiographic study. Neurosci Lett 133:154\u2013158","journal-title":"Neurosci Lett"},{"key":"523_CR10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","volume":"217","author":"RT Bartus","year":"1982","unstructured":"Bartus RT, Dean RL III, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408\u2013417","journal-title":"Science"},{"key":"523_CR11","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1017\/S0033291709990985","volume":"40","author":"F Beacher","year":"2010","unstructured":"Beacher F, Daly E, Simmons A, Prasher V, Morris R, Robinson C, Lovestone S, Murphy K, Murphy DGM (2010) Brain anatomy and ageing in non-demented adults with Down\u2019s syndrome: an in vivo MRI study. Psychol Med 40:611\u2013619","journal-title":"Psychol Med"},{"key":"523_CR12","doi-asserted-by":"crossref","first-page":"e0152471","DOI":"10.1371\/journal.pone.0152471","volume":"11","author":"PV Belichenko","year":"2016","unstructured":"Belichenko PV, Madani R, Rey-Bellet L et al (2016) An anti-\u03b2-amyloid vaccine for treating cognitive deficits in a mouse model of Down syndrome. PLoS One 11:e0152471","journal-title":"PLoS One"},{"key":"523_CR13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/neu.10116","volume":"53","author":"DK Berg","year":"2002","unstructured":"Berg DK, Conroy WG (2002) Nicotinic alpha 7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 53:512\u2013523","journal-title":"J Neurobiol"},{"key":"523_CR14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-3565(25)09528-X","volume":"273","author":"W Billard","year":"1995","unstructured":"Billard W, Binch H, Crosby G, Mcquade RD (1995) Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data. J Pharmacol Exp Ther 273:273\u2013279","journal-title":"J Pharmacol Exp Ther"},{"key":"523_CR15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1469-8749.2004.tb00483.x","volume":"46","author":"AH Bittles","year":"2004","unstructured":"Bittles AH, Glasson EJ (2004) Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol 46:282\u2013286","journal-title":"Dev Med Child Neurol"},{"key":"523_CR16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(22)00408-2","volume":"22","author":"AH Boerwinkle","year":"2023","unstructured":"Boerwinkle AH, Gordon BA, Wisch J et al (2023) Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer\u2019s disease: a cross-sectional study. Lancet Neurol 22:55\u201365","journal-title":"Lancet Neurol"},{"key":"523_CR17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","volume":"384","author":"SK Brannan","year":"2021","unstructured":"Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med 384:717\u2013726","journal-title":"N Engl J Med"},{"key":"523_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-3782(89)90019-4","volume":"18","author":"BWL Brooksbank","year":"1989","unstructured":"Brooksbank BWL, Walker D, Bal\u00e1zs R, Jorgensen OS (1989) Neuronal maturation in the foetal brain in Down\u2019s syndrome. Early Hum Dev 18:237\u2013246","journal-title":"Early Hum Dev"},{"key":"523_CR19","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1016\/j.cell.2021.11.001","volume":"184","author":"AJH Brown","year":"2021","unstructured":"Brown AJH, Bradley SJ, Marshall FH et al (2021) From structure to clinic: design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer\u2019s disease. Cell 184:5886\u20135901.e22","journal-title":"Cell"},{"key":"523_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-642-23274-9_7","volume":"208","author":"M Bubser","year":"2012","unstructured":"Bubser M, Byun N, Wood MR, Jones CK (2012) Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol 208:121\u2013166","journal-title":"Handb Exp Pharmacol"},{"key":"523_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210","journal-title":"J Prev Alzheimers Dis"},{"key":"523_CR22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1037\/0735-7044.100.4.476","volume":"100","author":"O Bure\u0161ov\u00e1","year":"1986","unstructured":"Bure\u0161ov\u00e1 O, Bolhuis JJ, Bure\u0161 J (1986) Differential effects of cholinergic blockade on performance of rats in the water tank navigation task and in a radial water maze. Behav Neurosci 100:476\u2013482","journal-title":"Behav Neurosci"},{"key":"523_CR23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.pneurobio.2012.02.004","volume":"98","author":"G Buzs\u00e1ki","year":"2012","unstructured":"Buzs\u00e1ki G, da Silva FL (2012) High frequency oscillations in the intact brain. Prog Neurobiol 98:241\u2013249","journal-title":"Prog Neurobiol"},{"key":"523_CR24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0197-4580(93)90090-X","volume":"14","author":"MJ Callahan","year":"1993","unstructured":"Callahan MJ, Kinsora JJ, Harbaugh RE, Reeder TM, Davis RE (1993) Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging 14:147\u2013151","journal-title":"Neurobiol Aging"},{"key":"523_CR25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/dneu.22709","volume":"79","author":"M Carmona-Iragui","year":"2019","unstructured":"Carmona-Iragui M, Videla L, Lle\u00f3 A, Fortea J (2019) Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: the complex triangle of brain amyloidosis. Dev Neurobiol 79:716\u2013737","journal-title":"Dev Neurobiol"},{"key":"523_CR26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ana.410180306","volume":"18","author":"MF Casanova","year":"1985","unstructured":"Casanova MF, Walker LC, Whitehouse PJ, Price DL (1985) Abnormalities of the nucleus basalis in Down\u2019s syndrome. Ann Neurol 18:310\u2013313","journal-title":"Ann Neurol"},{"key":"523_CR27","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0006-3495(95)80213-4","volume":"68","author":"NG Castro","year":"1995","unstructured":"Castro NG, Albuquerque EX (1995) Alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys J 68:516\u2013524","journal-title":"Biophys J"},{"key":"523_CR28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1460-9568.2004.03548.x","volume":"20","author":"KC Chen","year":"2004","unstructured":"Chen KC, Baxter MG, Rodefer JS (2004) Central blockade of muscarinic cholinergic receptors disrupts affective and attentional set-shifting. Eur J Neurosci 20:1081\u20131088","journal-title":"Eur J Neurosci"},{"key":"523_CR29","doi-asserted-by":"crossref","first-page":"10439","DOI":"10.1073\/pnas.181219298","volume":"98","author":"JD Cooper","year":"2001","unstructured":"Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC (2001) Failed retrograde transport of NGF in a mouse model of Down\u2019s syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci U S A 98:10439\u201310444","journal-title":"Proc Natl Acad Sci U S A"},{"key":"523_CR30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3233\/JAD-230141","volume":"95","author":"M Daamen","year":"2023","unstructured":"Daamen M, Scheef L, Li S et al (2023) Cortical amyloid burden relates to basal forebrain volume in subjective cognitive decline. J Alzheimers Dis 95:1013\u20131028","journal-title":"J Alzheimers Dis"},{"key":"523_CR31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.irn.2015.07.001","volume":"124","author":"JA Dani","year":"2015","unstructured":"Dani JA (2015) Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. Int Rev Neurobiol 124:3\u201319","journal-title":"Int Rev Neurobiol"},{"key":"523_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnana.2016.00001","volume":"10","author":"D Dautan","year":"2016","unstructured":"Dautan D, Bay HH, Bolam JP, Gerdjikov TV, Mena-Segovia J (2016) Extrinsic sources of cholinergic innervation of the striatal complex: a whole-brain mapping analysis. Front Neuroanat 10:1","journal-title":"Front Neuroanat"},{"key":"523_CR33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"308","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJF (1976) Selective loss of central cholinergic neurons in Alzheimer\u2019s disease. Lancet 308:1403","journal-title":"Lancet"},{"key":"523_CR34","first-page":"117","volume":"384","author":"MT Davisson","year":"1993","unstructured":"Davisson MT, Schmidt C, Reeves RH, Irving NG, Akeson EC, Harris BS, Bronson RT (1993) Segmental trisomy as a mouse model for Down syndrome. Prog Clin Biol Res 384:117\u2013133","journal-title":"Prog Clin Biol Res"},{"key":"523_CR35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.10069","volume":"51","author":"ST Dekosky","year":"2002","unstructured":"Dekosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145\u2013155","journal-title":"Ann Neurol"},{"key":"523_CR36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF02253533","volume":"111","author":"RP Dennes","year":"1993","unstructured":"Dennes RP, Barnes JC (1993) Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze. Psychopharmacology (Berl) 111:435\u2013441","journal-title":"Psychopharmacology (Berl)"},{"key":"523_CR37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Aducanumab: first approval. Drugs 81:1437\u20131443","journal-title":"Drugs"},{"key":"523_CR38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1042\/BJ20061451","volume":"404","author":"V Dorval","year":"2007","unstructured":"Dorval V, Mazzella MJ, Mathews PM, Hay RT, Fraser PE (2007) Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem J 404:309\u2013316","journal-title":"Biochem J"},{"key":"523_CR39","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)29217-X","volume":"299","author":"CL Douglas","year":"2001","unstructured":"Douglas CL, Baghdoyan HA, Lydic R (2001) M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57BL\/6J mouse. J Pharmacol Exp Ther 299:960\u2013966","journal-title":"J Pharmacol Exp Ther"},{"key":"523_CR40","first-page":"259","volume":"3","author":"JLH Down","year":"1866","unstructured":"Down JLH (1866) Observations on an ethnic classification of idiots. 1866. Ment Retard 3:259\u2013262","journal-title":"Ment Retard"},{"key":"523_CR41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","volume":"30","author":"DA Drachman","year":"1974","unstructured":"Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30:113","journal-title":"Arch Neurol"},{"key":"523_CR42","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pbb.2011.02.022","volume":"99","author":"JA Dumas","year":"2011","unstructured":"Dumas JA, Newhouse PA (2011) The cholinergic hypothesis of cognitive aging revisited again: cholinergic functional compensation. Pharmacol Biochem Behav 99:254\u2013261","journal-title":"Pharmacol Biochem Behav"},{"key":"523_CR43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1192\/bjp.2017.21","volume":"212","author":"N Eady","year":"2018","unstructured":"Eady N, Sheehan R, Rantell K et al (2018) Impact of cholinesterase inhibitors or memantine on survival in adults with Down syndrome and dementia: clinical cohort study. Br J Psychiatry 212:155\u2013160","journal-title":"Br J Psychiatry"},{"key":"523_CR44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S1461145705005407","volume":"9","author":"JR Ellis","year":"2006","unstructured":"Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF, Vitetta L, Nathan PJ (2006) Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 9:175\u2013189","journal-title":"Int J Neuropsychopharmacol"},{"key":"523_CR45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(21)00139-3","volume":"20","author":"AM Fagan","year":"2021","unstructured":"Fagan AM, Henson RL, Li Y et al (2021) Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer\u2019s disease: a cross-sectional study. Lancet Neurol 20:615\u2013626","journal-title":"Lancet Neurol"},{"key":"523_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci11030311","volume":"11","author":"MD Figueroa-Jimenez","year":"2021","unstructured":"Figueroa-Jimenez MD, Carb\u00f3-Carret\u00e9 M, Ca\u00f1ete-Mass\u00e9 C, Zarabozo-Hurtado D, Per\u00f3-Cebollero M, Salazar-Estrada JG, Gu\u00e0rdia-Olmos J (2021) Complexity analysis of the default mode network using resting-state fMRI in Down syndrome: relationships highlighted by a neuropsychological assessment. Brain Sci 11:1\u201319","journal-title":"Brain Sci"},{"key":"523_CR47","first-page":"301","volume":"7","author":"J Florez","year":"1990","unstructured":"Florez J, Del Arco C, Gonzalez A, Pascual J, Pazos A (1990) Autoradiographic studies of neurotransmitter receptors in the brain of newborn infants with Down syndrome. Am J Med Genet Suppl 7:301\u2013305","journal-title":"Am J Med Genet Suppl"},{"key":"523_CR48","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/S0021-9258(19)83646-3","volume":"260","author":"VA Florio","year":"1985","unstructured":"Florio VA, Sternweis PC (1985) Reconstitution of resolved muscarinic cholinergic receptors with purified GTP-binding proteins. J Biol Chem 260:3477\u20133483","journal-title":"J Biol Chem"},{"key":"523_CR49","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M (2021) Down syndrome-associated Alzheimer\u2019s disease: a genetic form of dementia. Lancet Neurol 20:930\u2013942","journal-title":"Lancet Neurol"},{"key":"523_CR50","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuron.2016.08.017","volume":"91","author":"DJ Foster","year":"2016","unstructured":"Foster DJ, Wilson JM, Remke DH et al (2016) Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron 91:1244\u20131252","journal-title":"Neuron"},{"key":"523_CR51","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hup.942","volume":"23","author":"A Fredrickson","year":"2008","unstructured":"Fredrickson A, Snyder PJ, Cromer J, Thomas E, Lewis M, Maruff P (2008) The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine. Hum Psychopharmacol 23:425\u2013436","journal-title":"Hum Psychopharmacol"},{"key":"523_CR52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","volume":"106","author":"S Garc\u00eda-Cerro","year":"2017","unstructured":"Garc\u00eda-Cerro S, Rueda N, Vidal V, Lantigua S, Mart\u00ednez-Cu\u00e9 C (2017) Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer\u2019s disease phenotypes. Neurobiol Dis 106:76\u201388","journal-title":"Neurobiol Dis"},{"key":"523_CR53","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/npp.2015.189","volume":"41","author":"A Ghoshal","year":"2016","unstructured":"Ghoshal A, Rook JM, Dickerson JW et al (2016) Potentiation of M1 muscarinic receptor reverses plasticity deficits and negative and cognitive symptoms in a schizophrenia mouse model. Neuropsychopharmacology 41:598\u2013610","journal-title":"Neuropsychopharmacology"},{"key":"523_CR54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1034\/j.1399-0004.2002.620506.x","volume":"62","author":"EJ Glasson","year":"2002","unstructured":"Glasson EJ, Sullivan SG, Hussain R, Petterson BA, Montgomery PD, Bittles AH (2002) The changing survival profile of people with Down\u2019s syndrome: implications for genetic counselling. Clin Genet 62:390\u2013393","journal-title":"Clin Genet"},{"key":"523_CR55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/B978-0-12-802206-1.00007-6","volume":"24","author":"JA Goldberg","year":"2016","unstructured":"Goldberg JA, Wilson CJ (2016) The cholinergic interneuron of the striatum. Handb Behav Neurosci 24:137\u2013155","journal-title":"Handb Behav Neurosci"},{"key":"523_CR56","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/s41386-020-00812-7","volume":"45","author":"RW Gould","year":"2020","unstructured":"Gould RW, Russell JK, Nedelcovych MT et al (2020) Modulation of arousal and sleep\/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates. Neuropsychopharmacology 45:2219\u20132228","journal-title":"Neuropsychopharmacology"},{"key":"523_CR57","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.pbb.2005.04.010","volume":"81","author":"A Green","year":"2005","unstructured":"Green A, Ellis KA, Ellis J, Bartholomeusz CF, Ilic S, Croft RJ, Luan Phan K, Nathan PJ, Phan KL, Nathan PJ (2005) Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav 81:575\u2013584","journal-title":"Pharmacol Biochem Behav"},{"key":"523_CR58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajmg.c.31439","volume":"169","author":"J Grieco","year":"2015","unstructured":"Grieco J, Pulsifer M, Seligsohn K, Skotko B, Schwartz A (2015) Down syndrome: cognitive and behavioral functioning across the lifespan. Am J Med Genet C Semin Med Genet 169:135\u2013149","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"523_CR59","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.neurobiolaging.2010.08.015","volume":"33","author":"C Haense","year":"2012","unstructured":"Haense C, Kalbe E, Herholz K, Hohmann C, Neumaier B, Krais R, Heiss WD (2012) Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging 33:867\u2013877","journal-title":"Neurobiol Aging"},{"key":"523_CR60","doi-asserted-by":"crossref","first-page":"e3186","DOI":"10.1002\/brb3.3186","volume":"13","author":"O Hamadelseed","year":"2023","unstructured":"Hamadelseed O, Skutella T (2023) Correlating MRI-based brain volumetry and cognitive assessment in people with Down syndrome. Brain Behav 13:e3186","journal-title":"Brain Behav"},{"key":"523_CR61","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/alz.13446","volume":"20","author":"SL Hartley","year":"2023","unstructured":"Hartley SL, Handen B, Tudorascu D et al (2023) AT(N) biomarker profiles and Alzheimer\u2019s disease symptomology in Down syndrome. Alzheimers Dement 20:366\u2013375","journal-title":"Alzheimers Dement"},{"key":"523_CR62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajmg.a.10074","volume":"116A","author":"JH Heller","year":"2003","unstructured":"Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS (2003) Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A 116A:111\u2013116","journal-title":"Am J Med Genet A"},{"key":"523_CR63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajmg.a.30184","volume":"130A","author":"JH Heller","year":"2004","unstructured":"Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS (2004) Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. Am J Med Genet A 130A:325\u2013326","journal-title":"Am J Med Genet A"},{"key":"523_CR64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1089\/cap.2006.16.755","volume":"16","author":"JH Heller","year":"2006","unstructured":"Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells RL, Li JS, Doraiswamy PM, Krishnan KR, Kishnani PS (2006) Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study. J Child Adolesc Psychopharmacol 16:755\u2013765","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"523_CR65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-180589","volume":"67","author":"AM Helman","year":"2019","unstructured":"Helman AM, Siever M, McCarty KL, Lott IT, Doran E, Abner EL, Schmitt FA, Head E (2019) Microbleeds and cerebral amyloid angiopathy in the brains of people with Down syndrome with Alzheimer\u2019s disease. J Alzheimers Dis 67:103\u2013112","journal-title":"J Alzheimers Dis"},{"key":"523_CR66","doi-asserted-by":"crossref","first-page":"13333","DOI":"10.1073\/pnas.93.23.13333","volume":"93","author":"DM Holtzman","year":"1996","unstructured":"Holtzman DM, Santucci D, Kilbridge J et al (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci U S A 93:13333\u201313338","journal-title":"Proc Natl Acad Sci U S A"},{"key":"523_CR67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Lecanemab: first approval. Drugs 83:359\u2013365","journal-title":"Drugs"},{"key":"523_CR68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ana.20250","volume":"56","author":"CL Hunter","year":"2004","unstructured":"Hunter CL, Bachman D, Granholm AC (2004) Minocycline prevents cholinergic loss in a mouse model of Down\u2019s syndrome. Ann Neurol 56:675\u2013688","journal-title":"Ann Neurol"},{"key":"523_CR69","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1352\/0895-8017(2003)108<367:EODOCF>2.0.CO;2","volume":"108","author":"N Johnson","year":"2003","unstructured":"Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D (2003) Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 108:367\u2013372","journal-title":"Am J Ment Retard"},{"key":"523_CR70","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin N, Llibre-Guerra JJ, Li Y et al (2022) Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of Gantenerumab and Solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann Neurol 92:729\u2013744","journal-title":"Ann Neurol"},{"key":"523_CR71","doi-asserted-by":"crossref","first-page":"100039","DOI":"10.1016\/j.nbas.2022.100039","volume":"2","author":"P Kanel","year":"2022","unstructured":"Kanel P, van der Zee S, Sanchez-Catasus CA, Koeppe RA, Scott PJH, van Laar T, Albin RL, Bohnen NI (2022) Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: a [18F]FEOBV PET study. Aging Brain 2:100039","journal-title":"Aging Brain"},{"key":"523_CR72","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","volume":"403","author":"I Kaul","year":"2023","unstructured":"Kaul I, Sawchak S, Correll CU, Kakar R, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK (2023) Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline\u2013trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 403:160\u2013170","journal-title":"Lancet"},{"key":"523_CR73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00726-015-2062-6","volume":"48","author":"S Keihan Falsafi","year":"2016","unstructured":"Keihan Falsafi S, Dierssen M, Ghafari M, Pollak A, Lubec G (2016) Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain. Amino Acids 48:103\u2013116","journal-title":"Amino Acids"},{"key":"523_CR74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.nicl.2014.11.015","volume":"7","author":"GM Kerbler","year":"2014","unstructured":"Kerbler GM, Fripp J, Rowe CC, Villemagne VL, Salvado O, Rose S, Coulson EJ (2014) Basal forebrain atrophy correlates with amyloid \u03b2 burden in Alzheimer\u2019s disease. Neuroimage Clin 7:105\u2013113","journal-title":"Neuroimage Clin"},{"key":"523_CR75","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1212\/WNL.44.6.1039","volume":"44","author":"JP Kesslak","year":"1994","unstructured":"Kesslak JP, Nagata SF, Lott I, Nalcioglu O (1994) Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down\u2019s syndrome. Neurology 44:1039\u20131045","journal-title":"Neurology"},{"key":"523_CR76","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1007\/s11064-022-03659-0","volume":"47","author":"M Kirstein","year":"2022","unstructured":"Kirstein M, Cambrils A, Segarra A, Melero A, Varea E (2022) Cholinergic senescence in the Ts65Dn mouse model for Down syndrome. Neurochem Res 47:3076\u20133092","journal-title":"Neurochem Res"},{"key":"523_CR77","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1471-4159.1989.tb01864.x","volume":"52","author":"S Kish","year":"1989","unstructured":"Kish S, Karlinsky H, Becker L, Gilbert J, Rebbetoy M, Chang L, DiStefano L, Hornykiewicz O (1989) Down\u2019s syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 52:1183\u20131187","journal-title":"J Neurochem"},{"key":"523_CR78","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/ajmg.a.32953","volume":"149A","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, Heller JH, Richardson S, McRae T (2009) The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A 149A:1641\u20131654","journal-title":"Am J Med Genet A"},{"key":"523_CR79","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1002\/ajmg.a.33730","volume":"152A","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, Zhang R, McRae T (2010) Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A 152A:3028\u20133035","journal-title":"Am J Med Genet A"},{"key":"523_CR80","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1866-1955-6-8","volume":"6","author":"MEI Koran","year":"2014","unstructured":"Koran MEI, Hohman TJ, Edwards CM et al (2014) Differences in age-related effects on brain volume in Down syndrome as compared to Williams syndrome and typical development. J Neurodev Disord 6:8","journal-title":"J Neurodev Disord"},{"key":"523_CR81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1176\/appi.ajp.159.1.74","volume":"159","author":"JS Krasuski","year":"2002","unstructured":"Krasuski JS, Alexander GE, Horwitz B, Rapoport SI, Schapiro MB (2002) Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down\u2019s syndrome: implications for the prodromal phase of Alzheimer\u2019s disease. Am J Psychiatry 159:74\u201381","journal-title":"Am J Psychiatry"},{"key":"523_CR82","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0306-4522(94)90341-7","volume":"62","author":"MG Lee","year":"1994","unstructured":"Lee MG, Chrobak JJ, Sik A, Wiley RG, Buzs\u00e1ki G (1994) Hippocampal theta activity following selective lesion of the septal cholinergic system. Neuroscience 62:1033\u20131047","journal-title":"Neuroscience"},{"key":"523_CR83","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-3016.2000.00252.x","volume":"14","author":"S Leonard","year":"2000","unstructured":"Leonard S, Bower C, Petterson B, Leonard H (2000) Survival of infants born with Down\u2019s syndrome: 1980\u201396. Paediatr Perinat Epidemiol 14:163\u2013171","journal-title":"Paediatr Perinat Epidemiol"},{"key":"523_CR84","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00213-005-0164-7","volume":"184","author":"ED Levin","year":"2005","unstructured":"Levin ED, McClernon FJ, Rezvani AH (2005) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184:523\u2013539","journal-title":"Psychopharmacology (Berl)"},{"key":"523_CR85","doi-asserted-by":"publisher","unstructured":"Li W, Wang Y, Lohith TG et al (2022) The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer\u2019s disease. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abg3684","DOI":"10.1126\/scitranslmed.abg3684"},{"key":"523_CR86","doi-asserted-by":"crossref","first-page":"114062","DOI":"10.1016\/j.ejmech.2021.114062","volume":"229","author":"T Liu","year":"2022","unstructured":"Liu T, Wang Y, Wang J, Ren C, Chen H, Zhang J (2022) DYRK1A inhibitors for disease therapy: current status and perspectives. Eur J Med Chem 229:114062","journal-title":"Eur J Med Chem"},{"key":"523_CR87","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/archneur.59.7.1133","volume":"59","author":"IT Lott","year":"2002","unstructured":"Lott IT, Osann K, Doran E, Nelson L (2002) Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol 59:1133\u20131136","journal-title":"Arch Neurol"},{"key":"523_CR88","doi-asserted-by":"crossref","unstructured":"Lubec B, Yoo BC, Dierssen M, Balic N, Lubec G (2001) Down syndrome patients start early prenatal life with normal cholinergic, monoaminergic and serotoninergic innervation. J Neural Transm Suppl:303\u2013310","DOI":"10.1007\/978-3-7091-6262-0_25"},{"key":"523_CR89","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0079-6123(08)60908-5","volume":"84","author":"MM Mesulam","year":"1990","unstructured":"Mesulam MM (1990) Human brain cholinergic pathways. Prog Brain Res 84:231\u2013241","journal-title":"Prog Brain Res"},{"key":"523_CR90","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cne.902140206","volume":"214","author":"M-M Mesulam","year":"1983","unstructured":"Mesulam M-M, Mufson EJ, Levey AI, Wainer BH (1983) Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214:170\u2013197","journal-title":"J Comp Neurol"},{"key":"523_CR91","doi-asserted-by":"crossref","first-page":"9767","DOI":"10.1016\/S0021-9258(17)36949-1","volume":"269","author":"JC Migeon","year":"1994","unstructured":"Migeon JC, Nathanson NM (1994) Differential regulation of cAMP-mediated gene transcription by m1 and m4 muscarinic acetylcholine receptors. Preferential coupling of m4 receptors to Gi alpha-2. J Biol Chem 269:9767\u20139773","journal-title":"J Biol Chem"},{"key":"523_CR92","doi-asserted-by":"crossref","first-page":"16070","DOI":"10.1074\/jbc.270.27.16070","volume":"270","author":"JC Migeon","year":"1995","unstructured":"Migeon JC, Thomas SL, Nathanson NM (1995) Differential coupling of m2 and m4 muscarinic receptors to inhibition of adenylyl cyclase by Gi alpha and G(o)alpha subunits. J Biol Chem 270:16070\u201316074","journal-title":"J Biol Chem"},{"key":"523_CR93","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/s41386-018-0033-9","volume":"43","author":"SP Moran","year":"2018","unstructured":"Moran SP, Dickerson JW, Cho HP et al (2018) M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Neuropsychopharmacology 43:1763\u20131771","journal-title":"Neuropsychopharmacology"},{"key":"523_CR94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0301-0082(98)00059-8","volume":"57","author":"EJ Mufson","year":"1999","unstructured":"Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T (1999) Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 57:451\u2013484","journal-title":"Prog Neurobiol"},{"key":"523_CR95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-011-0884-1","volume":"123","author":"EJ Mufson","year":"2012","unstructured":"Mufson EJ, Binder L, Counts SE, Dekosky ST, Detoledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123:13","journal-title":"Acta Neuropathol"},{"key":"523_CR96","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41380-018-0130-5","volume":"24","author":"S Nejad-Davarani","year":"2019","unstructured":"Nejad-Davarani S, Koeppe RA, Albin RL, Frey KA, M\u00fcller MLTM, Bohnen NI (2019) Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV. Mol Psychiatry 24:322\u2013327","journal-title":"Mol Psychiatry"},{"key":"523_CR97","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41598-018-20984-z","volume":"8","author":"F Neumann","year":"2018","unstructured":"Neumann F, Gourdain S, Albac C et al (2018) DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep 8:2859","journal-title":"Sci Rep"},{"key":"523_CR98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/npp.1994.11","volume":"10","author":"PA Newhouse","year":"1994","unstructured":"Newhouse PA, Potter A, Corwin J, Lenox R (1994) Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 10:93\u2013107","journal-title":"Neuropsychopharmacology"},{"key":"523_CR99","doi-asserted-by":"crossref","first-page":"P1255","DOI":"10.1016\/j.jalz.2017.06.1870","volume":"13","author":"PA Newhouse","year":"2017","unstructured":"Newhouse PA, Conley AC, Key AP (2017) Exploring novel cognitive and electrophysiological markers of target engagement in phase 1 and 2 studies of putative cholinergic cognitive enhancers. Alzheimers Dement 13:P1255\u2013P1256","journal-title":"Alzheimers Dement"},{"key":"523_CR100","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jnr.21035","volume":"84","author":"P Opazo","year":"2006","unstructured":"Opazo P, Saud K, De Saint PM, C\u00e1rdenas AM, Allen DD, Segura-Aguilar J, Caviedes R, Caviedes P (2006) Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: an animal model of down syndrome. J Neurosci Res 84:1303\u20131310","journal-title":"J Neurosci Res"},{"key":"523_CR101","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/cn500003z","volume":"5","author":"T Pancani","year":"2014","unstructured":"Pancani T, Bolarinwa C, Smith Y, Lindsley CW, Conn PJ, Xiang Z (2014) M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses. ACS Chem Neurosci 5:318\u2013324","journal-title":"ACS Chem Neurosci"},{"key":"523_CR102","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuron.2007.08.025","volume":"56","author":"V Parikh","year":"2007","unstructured":"Parikh V, Kozak R, Martinez V, Sarter M (2007) Prefrontal acetylcholine release controls Cue detection on multiple timescales. Neuron 56:141\u2013154","journal-title":"Neuron"},{"key":"523_CR103","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5607\/en.2013.22.4.244","volume":"22","author":"J Park","year":"2013","unstructured":"Park J, Chung KC (2013) New perspectives of Dyrk1A Role in neurogenesis and Neuropathologic features of Down syndrome. Exp Neurobiol 22:244\u2013248","journal-title":"Exp Neurobiol"},{"key":"523_CR104","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/alz.12229","volume":"17","author":"R Pentz","year":"2021","unstructured":"Pentz R, Iulita MF, Ducatenzeiler A, Videla L, Benejam B, Iragui MC, Blesa R, Lle\u00f3 A, Fortea J, Cuello AC (2021) Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer\u2019s disease: a paired CSF and plasma study. Alzheimers Dement 17:605\u2013617","journal-title":"Alzheimers Dement"},{"key":"523_CR105","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1212\/WNL.56.7.972","volume":"56","author":"JD Pinter","year":"2001","unstructured":"Pinter JD, Brown WE, Eliez S, Schmitt JE, Capone GT, Reiss AL (2001) Amygdala and hippocampal volumes in children with Down syndrome: a high-resolution MRI study. Neurology 56:972\u2013974","journal-title":"Neurology"},{"key":"523_CR106","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1007\/s00429-015-1164-y","volume":"221","author":"BE Powers","year":"2016","unstructured":"Powers BE, Velazquez R, Kelley CM, Ash JA, Strawderman MS, Alldred MJ, Ginsberg SD, Mufson EJ, Strupp BJ (2016) Attentional function and basal forebrain cholinergic neuron morphology during aging in the Ts65Dn mouse model of Down syndrome. Brain Struct Funct 221:4337\u20134352","journal-title":"Brain Struct Funct"},{"key":"523_CR107","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/gps.587","volume":"17","author":"VP Prasher","year":"2002","unstructured":"Prasher VP, Huxley A, Haque MS (2002) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer\u2019s disease \u2013 pilot study. Int J Geriatr Psychiatry 17:270\u2013278","journal-title":"Int J Geriatr Psychiatry"},{"key":"523_CR108","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/gps.859","volume":"18","author":"VP Prasher","year":"2003","unstructured":"Prasher VP, Adams C, Holder R et al (2003) Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer\u2019s disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry 18:549\u2013551","journal-title":"Int J Geriatr Psychiatry"},{"key":"523_CR109","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/gps.1306","volume":"20","author":"VP Prasher","year":"2005","unstructured":"Prasher VP, Fung N, Adams C (2005) Rivastigmine in the treatment of dementia in Alzheimer\u2019s disease in adults with Down syndrome. Int J Geriatr Psychiatry 20:496\u2013497","journal-title":"Int J Geriatr Psychiatry"},{"key":"523_CR110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gps.3821","volume":"28","author":"VP Prasher","year":"2013","unstructured":"Prasher VP, Sachdeva N, Adams C, Haque MS (2013) Rivastigmine transdermal patches in the treatment of dementia in Alzheimer\u2019s disease in adults with Down syndrome-pilot study. Int J Geriatr Psychiatry 28:219\u2013220","journal-title":"Int J Geriatr Psychiatry"},{"key":"523_CR111","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.nicl.2018.01.024","volume":"18","author":"J Pujol","year":"2018","unstructured":"Pujol J, Fenoll R, Ribas-Vidal N, Mart\u00ednez-Vilavella G, Blanco-Hinojo L, Garc\u00eda-Alba J, Deus J, Novell R, Esteba-Castillo S (2018) A longitudinal study of brain anatomy changes preceding dementia in Down syndrome. Neuroimage Clin 18:160\u2013166","journal-title":"Neuroimage Clin"},{"key":"523_CR112","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1001\/jama.2023.22924","volume":"22","author":"MS Rafii","year":"2023","unstructured":"Rafii MS, Fortea J (2023) Down syndrome in a new era for Alzheimer disease. JAMA 22:2157\u20132158","journal-title":"JAMA"},{"key":"523_CR113","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/B978-0-12-804766-8.00017-0","volume":"167","author":"MS Rafii","year":"2019","unstructured":"Rafii MS, Kleschevnikov AM, Sawa M, Mobley WC (2019) Down syndrome. Handb Clin Neurol 167:321\u2013336","journal-title":"Handb Clin Neurol"},{"key":"523_CR114","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"MA Raskind","year":"2000","unstructured":"Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 study group. Neurology 54:2261\u20132268","journal-title":"Neurology"},{"key":"523_CR115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0361-9230(86)90076-6","volume":"16","author":"RH Reeves","year":"1986","unstructured":"Reeves RH, Gearhart JD, Littlefield JW (1986) Genetic basis for a mouse model of down syndrome. Brain Res Bull 16:803\u2013814","journal-title":"Brain Res Bull"},{"key":"523_CR116","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ng1095-177","volume":"11","author":"RH Reeves","year":"1995","unstructured":"Reeves RH, Irving NG, Moran TH, Wohn A, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT (1995) A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet 11:177\u2013184","journal-title":"Nat Genet"},{"key":"523_CR117","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.neuroimage.2014.06.031","volume":"100","author":"N Richter","year":"2014","unstructured":"Richter N, Allendorf I, Onur OA, Kracht L, Dietlein M, Tittgemeyer M, Neumaier B, Fink GR, Kukolja J (2014) The integrity of the cholinergic system determines memory performance in healthy elderly. Neuroimage 100:481\u2013488","journal-title":"Neuroimage"},{"key":"523_CR118","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JAD-210261","volume":"86","author":"N Richter","year":"2022","unstructured":"Richter N, David LS, Grothe MJ, Teipel S, Dietlein M, Tittgemeyer M, Neumaier B, Fink GR, Onur OA, Kukolja J (2022) Age and anterior basal forebrain volume predict the cholinergic deficit in patients with mild cognitive impairment due to Alzheimer\u2019s disease. J Alzheimers Dis 86:425\u2013440","journal-title":"J Alzheimers Dis"},{"key":"523_CR119","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group. Neurology 50:136\u2013145","journal-title":"Neurology"},{"key":"523_CR120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","volume":"318","author":"M R\u00f6sler","year":"1999","unstructured":"R\u00f6sler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, St\u00e4helin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial. BMJ 318:633\u2013638","journal-title":"BMJ"},{"key":"523_CR121","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1002\/alz.12999","volume":"19","author":"M Rozalem Aranha","year":"2023","unstructured":"Rozalem Aranha M, Iulita MF, Montal V et al (2023) Basal forebrain atrophy along the Alzheimer\u2019s disease continuum in adults with Down syndrome. Alzheimers Dement 19:4817\u20134827","journal-title":"Alzheimers Dement"},{"key":"523_CR122","doi-asserted-by":"crossref","first-page":"e082662","DOI":"10.1002\/alz.082662","volume":"19","author":"JK Russell","year":"2023","unstructured":"Russell JK, Conley AC, Boyd BD, Schlossberg R, Rosenberg AJ, Acosta LMY, Shokouhi S, Newhouse PA (2023a) A pilot study assessing central cholinergic integrity in individuals with Down syndrome using [18F]-FEOBV PET and basal forebrain cholinergic anatomy. Alzheimers Dement 19:e082662","journal-title":"Alzheimers Dement"},{"key":"523_CR123","first-page":"S105","volume":"10","author":"JK Russell","year":"2023","unstructured":"Russell JK, Conley AC, Boyd BD, Schlossberg R, Rosenberg AJ, Acosta LMY, Rafii MS, Shokouhi S, Newhouse PA (2023b) Assessing the relationship between central cholinergic integrity and amyloid accumulation in individuals with Down syndrome using [18F]-FEOBV and [11C]-PIB PET: preliminary data. J Prev Alzheimers Dis 10:S105","journal-title":"J Prev Alzheimers Dis"},{"key":"523_CR124","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0306-4522(84)90083-6","volume":"13","author":"DB Rye","year":"1984","unstructured":"Rye DB, Wainer BH, Mesulam MM, Mufson EJ, Saper CB (1984) Cortical projections arising from the basal forebrain: a study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience 13:627\u2013643","journal-title":"Neuroscience"},{"key":"523_CR125","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","volume":"282","author":"SR Ryoo","year":"2007","unstructured":"Ryoo SR, Hey KJ, Radnaabazar C et al (2007) DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J Biol Chem 282:34850\u201334857","journal-title":"J Biol Chem"},{"key":"523_CR126","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","volume":"104","author":"SR Ryoo","year":"2008","unstructured":"Ryoo SR, Cho HJ, Lee HW et al (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease. J Neurochem 104:1333\u20131344","journal-title":"J Neurochem"},{"key":"523_CR127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2006.05.022","volume":"51","author":"A Salehi","year":"2006","unstructured":"Salehi A, Delcroix JD, Belichenko PV et al (2006) Increased app expression in a mouse model of Down\u2019s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51:29\u201342","journal-title":"Neuron"},{"key":"523_CR128","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.brainresrev.2004.08.006","volume":"48","author":"M Sarter","year":"2005","unstructured":"Sarter M, Hasselmo ME, Bruno JP, Givens B (2005) Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Brain Res Rev 48:98\u2013111","journal-title":"Brain Res Brain Res Rev"},{"key":"523_CR129","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cne.902530302","volume":"253","author":"K Satoh","year":"1986","unstructured":"Satoh K, Fibiger HC (1986) Cholinergic neurons of the laterodorsal tegmental nucleus: efferent and afferent connections. J Comp Neurol 253:277\u2013302","journal-title":"J Comp Neurol"},{"key":"523_CR130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41398-022-02254-9","volume":"12","author":"C Sauder","year":"2022","unstructured":"Sauder C, Allen LA, Baker E, Miller AC, Paul SM, Brannan SK (2022) Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study. Transl Psychiatry 12:491","journal-title":"Transl Psychiatry"},{"key":"523_CR131","doi-asserted-by":"crossref","first-page":"101612","DOI":"10.1016\/j.nicl.2018.101612","volume":"21","author":"L Scheef","year":"2019","unstructured":"Scheef L, Grothe MJ, Koppara A, Daamen M, Boecker H, Biersack H, Schild HH, Wagner M, Teipel S, Jessen F (2019) Subregional volume reduction of the cholinergic forebrain in subjective cognitive decline (SCD). Neuroimage Clin 21:101612","journal-title":"Neuroimage Clin"},{"key":"523_CR132","first-page":"1","volume":"7","author":"TW Schmitz","year":"2016","unstructured":"Schmitz TW, Nathan Spreng R (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer\u2019s pathology. Nat Commun 7:1\u201313","journal-title":"Nat Commun"},{"key":"523_CR133","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1523\/JNEUROSCI.13-02-00596.1993","volume":"13","author":"P Seguela","year":"1993","unstructured":"Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13:596\u2013604","journal-title":"J Neurosci"},{"key":"523_CR134","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.expneurol.2004.11.017","volume":"193","author":"H Seo","year":"2005","unstructured":"Seo H, Isacson O (2005) Abnormal APP, cholinergic and cognitive function in Ts65Dn Down\u2019s model mice. Exp Neurol 193:469\u2013480","journal-title":"Exp Neurol"},{"key":"523_CR135","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1021\/bi00142a026","volume":"31","author":"K Shaw","year":"1992","unstructured":"Shaw K, Exton JH (1992) Identification in bovine liver plasma membranes of a Gq-activatable phosphoinositide phospholipase C. Biochemistry 31:6347\u20136354","journal-title":"Biochemistry"},{"key":"523_CR136","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1037\/0735-7044.117.3.526","volume":"117","author":"SJ Sherman","year":"2003","unstructured":"Sherman SJ, Hasselmo ME, Atri A, Stern CE, Howard MW (2003) Scopolamine impairs human recognition memory: data and modeling. Behav Neurosci 117:526\u2013539","journal-title":"Behav Neurosci"},{"key":"523_CR137","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ajmg.a.31790","volume":"143A","author":"GA Spiridigliozzi","year":"2007","unstructured":"Spiridigliozzi GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells R, Dawson D, Li J, Kishnani PS (2007) Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med Genet A 143A:1408\u20131413","journal-title":"Am J Med Genet A"},{"key":"523_CR138","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/ajmg.a.37650","volume":"170","author":"GA Spiridigliozzi","year":"2016","unstructured":"Spiridigliozzi GA, Hart SJ, Heller JH, Schneider HE, Baker JA, Weadon C, Capone GT, Kishnani PS (2016) Safety and efficacy of rivastigmine in children with Down syndrome: a double blind placebo controlled trial. Am J Med Genet A 170:1545\u20131555","journal-title":"Am J Med Genet A"},{"key":"523_CR139","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0278-5846(86)90030-8","volume":"10","author":"T Sunderland","year":"1986","unstructured":"Sunderland T, Tariot PN, Weingartner H, Murphy DL, Newhouse PA, Mueller EA, Cohen RM (1986) Pharmacologic modelling of Alzheimer\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 10:599\u2013610","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"523_CR140","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0165-0173(88)90013-6","volume":"13","author":"T Sunderland","year":"1988","unstructured":"Sunderland T, Tariot PN, Newhouse PA (1988) Differential responsivity of mood, behavior and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 13:371\u2013389","journal-title":"Brain Res Rev"},{"key":"523_CR141","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0926-6410(99)00021-X","volume":"8","author":"MA Taffe","year":"1999","unstructured":"Taffe MA, Weed MR, Gold LH (1999) Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Cogn Brain Res 8:203\u2013212","journal-title":"Cogn Brain Res"},{"key":"523_CR142","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0888-7543(88)90143-7","volume":"3","author":"RE Tanzi","year":"1988","unstructured":"Tanzi RE, Haines JL, Watkins PC, Stewart GD, Wallace MR, Hallewell R, Wong C, Wexler NS, Conneally PM, Gusella JF (1988) Genetic linkage map of human chromosome 21. Genomics 3:129\u2013136","journal-title":"Genomics"},{"key":"523_CR143","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/brain\/awh101","volume":"127","author":"SJ Teipel","year":"2004","unstructured":"Teipel SJ, Alexander GE, Schapiro MB, M\u00f6ller HJ, Rapoport SI, Hampel H (2004) Age-related cortical grey matter reductions in non-demented Down\u2019s syndrome adults determined by MRI with voxel-based morphometry. Brain 127:811\u2013824","journal-title":"Brain"},{"key":"523_CR144","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"AV Terry","year":"2003","unstructured":"Terry AV, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821\u2013827","journal-title":"J Pharmacol Exp Ther"},{"key":"523_CR145","doi-asserted-by":"crossref","first-page":"33S","DOI":"10.2967\/jnumed.121.263198","volume":"63","author":"S Tiepolt","year":"2022","unstructured":"Tiepolt S, Meyer PM, Patt M, Deuther-Conrad W, Hesse S, Barthel H, Sabri O (2022) PET imaging of cholinergic neurotransmission in neurodegenerative disorders. J Nucl Med 63:33S\u201344S","journal-title":"J Nucl Med"},{"key":"523_CR146","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1741-1130.2010.00249.x","volume":"7","author":"J Torr","year":"2010","unstructured":"Torr J, Strydom A, Patti P, Jokinen N (2010) Aging in Down syndrome: morbidity and mortality. J Policy Pract Intellect Disabil 7:70\u201381","journal-title":"J Policy Pract Intellect Disabil"},{"key":"523_CR147","first-page":"e12096","volume":"6","author":"DL Tudorascu","year":"2020","unstructured":"Tudorascu DL, Laymon CM, Zammit M et al (2020) Relationship of amyloid beta and neurofibrillary tau deposition in neurodegeneration in aging Down syndrome (NiAD) study at baseline. Alzheimer\u2019s Dementia 6:e12096","journal-title":"Alzheimer\u2019s Dementia"},{"key":"523_CR148","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.mp.4001270","volume":"8","author":"ET Tzavara","year":"2003","unstructured":"Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG (2003) Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2\/M4 muscarinic receptor knockout mice. Mol Psychiatry 8:673\u2013679","journal-title":"Mol Psychiatry"},{"key":"523_CR149","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.117.245894","volume":"365","author":"JM Uslaner","year":"2018","unstructured":"Uslaner JM, Kuduk SD, Wittmann M et al (2018) Preclinical to human translational pharmacology of the novel M1 positive allosteric modulator MK-7622. J Pharmacol Exp Ther 365:556\u2013566","journal-title":"J Pharmacol Exp Ther"},{"key":"523_CR150","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:142\u2013143","journal-title":"N Engl J Med"},{"key":"523_CR151","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/brain.2014.0266","volume":"5","author":"JN Vega","year":"2015","unstructured":"Vega JN, Hohman TJ, Pryweller JR, Dykens EM, Thornton-Wells TA (2015) Resting-state functional connectivity in individuals with Down syndrome and Williams syndrome compared with typically developing controls. Brain Connect 5:461\u2013475","journal-title":"Brain Connect"},{"key":"523_CR152","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2023.2163","volume":"9","author":"A Verma","year":"2023","unstructured":"Verma A, Lupo PJ, Shah NN, Hitzler J, Rabin KR (2023) Management of Down syndrome-associated Leukemias: a review. JAMA Oncol 9:1283\u20131290","journal-title":"JAMA Oncol"},{"key":"523_CR153","first-page":"173","volume":"4","author":"T Voss","year":"2018","unstructured":"Voss T, Li J, Cummings J et al (2018) Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia 4:173\u2013181","journal-title":"Alzheimer\u2019s Dementia"},{"key":"523_CR154","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/cne.902840212","volume":"284","author":"E Wada","year":"1989","unstructured":"Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson LW (1989) Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J Comp Neurol 284:314\u2013335","journal-title":"J Comp Neurol"},{"key":"523_CR155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000118998","volume":"28","author":"DM Warburton","year":"1993","unstructured":"Warburton DM, Rusted JM (1993) Cholinergic control of cognitive resources. Neuropsychobiology 28:43\u201346","journal-title":"Neuropsychobiology"},{"key":"523_CR156","first-page":"20","volume":"6","author":"BD Waterhouse","year":"2012","unstructured":"Waterhouse BD, Chandler D (2012) Evidence for broad versus segregated projections from cholinergic and noradrenergic nuclei to functionally and anatomically discrete subregions of prefrontal cortex. Front Behav Neurosci 6:20","journal-title":"Front Behav Neurosci"},{"key":"523_CR157","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1053-8119(03)00273-8","volume":"20","author":"NS White","year":"2003","unstructured":"White NS, Alkire MT, Haier RJ (2003) A voxel-based morphometric study of nondemented adults with Down syndrome. Neuroimage 20:393\u2013403","journal-title":"Neuroimage"},{"key":"523_CR158","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"PJ Whitehouse","year":"1979","unstructured":"Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1979) DeLong M (1982) Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237\u20131239","journal-title":"Science"},{"key":"523_CR159","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ana.410100203","volume":"10","author":"PJ Whitehouse","year":"1981","unstructured":"Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981) Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122\u2013126","journal-title":"Ann Neurol"},{"key":"523_CR160","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/brain\/awy159","volume":"141","author":"FK Wiseman","year":"2018","unstructured":"Wiseman FK, Pulford LJ, Barkus C et al (2018) Trisomy of human chromosome 21 enhances amyloid-\u03b2 deposition independently of an extra copy of APP. Brain 141:2457\u20132474","journal-title":"Brain"},{"key":"523_CR161","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ana.410170310","volume":"17","author":"K Wisniewski","year":"1985","unstructured":"Wisniewski K, Wisniewski H, Wen G (1985) Occurrence of neuropathological changes and dementia of Alzheimer\u2019s disease in Down\u2019s syndrome. Ann Neurol 17:278\u2013282","journal-title":"Ann Neurol"},{"key":"523_CR162","doi-asserted-by":"crossref","first-page":"102992","DOI":"10.1016\/j.nicl.2022.102992","volume":"34","author":"Y Xia","year":"2022","unstructured":"Xia Y, Eeles E, Fripp J et al (2022) Reduced cortical cholinergic innervation measured using [18F]-FEOBV PET imaging correlates with cognitive decline in mild cognitive impairment. Neuroimage Clin 34:102992","journal-title":"Neuroimage Clin"},{"key":"523_CR163","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neurobiolaging.2023.09.002","volume":"132","author":"Y Xia","year":"2023","unstructured":"Xia Y, Maruff P, Dor\u00e9 V et al (2023) Longitudinal trajectories of basal forebrain volume in normal aging and Alzheimer\u2019s disease. Neurobiol Aging 132:120\u2013130","journal-title":"Neurobiol Aging"},{"key":"523_CR164","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41598-017-00682-y","volume":"7","author":"X Yin","year":"2017","unstructured":"Yin X, Jin N, Shi J, Zhang Y, Wu Y, Gong CX, Iqbal K, Liu F (2017) Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice. Sci Rep 7:619","journal-title":"Sci Rep"},{"key":"523_CR165","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bcp.14975","volume":"88","author":"W Yin","year":"2022","unstructured":"Yin W, Mamashli F, Buhl DL, Khudyakov P, Volfson D, Martenyi F, Gevorkyan H, Rosen L, Simen AA (2022) Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. Br J Clin Pharmacol 88:600\u2013612","journal-title":"Br J Clin Pharmacol"},{"key":"523_CR166","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0893-6080(02)00058-8","volume":"15","author":"AJ Yu","year":"2002","unstructured":"Yu AJ, Dayan P (2002) Acetylcholine in cortical inference. Neural Netw 15:719\u2013730","journal-title":"Neural Netw"},{"key":"523_CR167","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2005.04.026","volume":"46","author":"AJ Yu","year":"2005","unstructured":"Yu AJ, Dayan P (2005) Uncertainty, neuromodulation, and attention. Neuron 46:681\u2013692","journal-title":"Neuron"},{"key":"523_CR168","doi-asserted-by":"crossref","first-page":"102740","DOI":"10.1016\/j.nicl.2021.102740","volume":"31","author":"MD Zammit","year":"2021","unstructured":"Zammit MD, Tudorascu DL, Laymon CM et al (2021) Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. Neuroimage Clin 31:102740","journal-title":"Neuroimage Clin"},{"key":"523_CR169","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/hmg\/ddt446","volume":"23","author":"L Zhang","year":"2014","unstructured":"Zhang L, Meng K, Jiang X et al (2014) Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits. Hum Mol Genet 23:578\u2013589","journal-title":"Hum Mol Genet"},{"key":"523_CR170","doi-asserted-by":"crossref","first-page":"e2016432118","DOI":"10.1073\/pnas.2016432118","volume":"118","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Cao L, Varga V, Jing M, Karadas M, Li Y, Buzs\u00e1ki G (2021) Cholinergic suppression of hippocampal sharp-wave ripples impairs working memory. Proc Natl Acad Sci U S A 118:e2016432118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"523_CR171","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ddrr.1128","volume":"18","author":"WB Zigman","year":"2013","unstructured":"Zigman WB (2013) Atypical aging in Down syndrome. Dev Disabil Res Rev 18:51\u201367","journal-title":"Dev Disabil Res Rev"}],"container-title":["Current Topics in Behavioral Neurosciences","Neurobiology of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2024_523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:47:55Z","timestamp":1757951275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2024_523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783031849190","9783031849206"],"references-count":171,"URL":"https:\/\/doi.org\/10.1007\/7854_2024_523","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2 November 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}